Results for the substance abemaciclib

Abemaciclib is a medication used in the treatment of certain types of advanced or metastatic breast cancer. It belongs to the class of cyclin-dependent kinase (CDK4/6) inhibitors and is used in combination with other hormonal therapies (such as fulvestrant) or as monotherapy in patients with HR-positive (hormone receptor-positive) and HER2-negative (human epidermal growth factor receptor 2-negative) breast cancer.

Abemaciclib works by inhibiting the CDK4 and CDK6 enzymes, which are involved in cell division. By blocking these enzymes, the medication slows the growth and multiplication of cancer cells, helping to control disease progression.

The medication is taken orally, usually twice daily, as directed by a doctor. The dosage may be adjusted based on the patient's tolerance and side effects.

Common side effects include diarrhea, nausea, fatigue, loss of appetite, vomiting, and a decrease in white blood cell count (neutropenia). Rarely, more severe reactions such as infections, liver function impairment, or blood clots may occur.

Patients should be regularly monitored during treatment, including blood tests to check liver function and blood cell counts. It is important for patients to inform their doctor about any side effects or other medications they are taking, as abemaciclib may interact with other treatments.